Side-by-side · Research reference

BPC-157vsPancragen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED9/53 cited

BAnimal-StrongHUMAN-REVIEWED23/39 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

Pancragen

Bioregulatory Tetrapeptide · Khavinson School

50 μgPrimate doseGoncharova 2014

10 daysTreatment cycleGoncharova 2015

3+ weeksEffect persistenceGoncharova 2014

IM · 10-day cycleGoncharova 2014

01Mechanism of Action

Parameter

BPC-157

Pancragen

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011 Sikiric 2018

Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011

Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014

Feedback intact?

No known endogenous receptor; mechanism still under investigation

Yes — preserves physiological glucose-insulin response

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

Pancragen

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

—

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Once daily for 10 daysGoncharova 2014

Lower / starter dose

200 mcg / day

Conservative starter for new users.

—

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Non-human primate RCT, in vitro cell cultureGoncharova 2015 Khavinson 2013

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

—

Reconstitution

Bacteriostatic water, 1–2 mL

—

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

—

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

—

Primate dose (rhesus macaque)

—

50 μg / animal / dayGoncharova 2014

20–25-year-old females, 10-day IM protocol.

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic tissue culture, both young and aged rat explants.

Route

—

IntramuscularGoncharova 2015

Treatment cycle

—

10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014

Diabetes model

—

STZ-induced diabetes (rat)

Evaluated via metabolic markers characterizing apoptosis.

04Side Effects & Safety

Parameter

BPC-157

Pancragen

Injection site reaction

Mild irritation (anecdotal)

—

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Long-term safety

Unknown beyond Phase 2 trial duration

—

Drug interactions

None established

—

Reported adverse events

—

None documented in primate studies

Tolerability

—

Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015

Human safety data

—

No published human trials; clinical use limited to Russian gerontology protocols

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Pancragen

—

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

Pancragen

·Active pancreatic malignancy (proliferation marker upregulation)

05Administration Protocol

Parameter

BPC-157

Pancragen

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

No specific timing constraints documented. Administered once daily in primate protocols.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

—

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

Pancragen

— no documented stacks